大剂量阿托伐他汀联合尿激酶治疗急性脑梗死的临床疗效

王佩军

（陕西省千阳县人民医院神经内科，陕西 宝鸡，721100）

浏览次数：146次 下载次数：370次

摘要：

目的 探讨急性脑梗死患者应用大剂量阿托伐他汀联合尿激酶治疗的临床疗效。方法 选择我院收治的78例急性脑梗死患者，随机分为观察组及对照组，每组39例。观察组患者给予40 mg/d阿托伐他汀+尿激酶，对照组患者给予10 mg/d 阿托伐他汀+尿激酶，观察两组患者治疗前，治疗后1、7、14 d 的ESS评分，治疗后的临床效果及不良反应发生情况。结果 治疗前 1天，两组患者的ESS评分比较差异无统计学意义（P>0.05）；治疗后1、7、14 天两组患者的ESS评分均明显升高（P<0.05），且与对照组相比，观察组患者的ESS评分明显较高（P<0.05）。观察组患者的治疗总有效率高于对照组（P<0.05）。两组患者的不良反应发生情况比较无明显差异（P>0.05）。结论 大剂量阿托伐他汀联合尿激酶治疗急性脑梗死，可有效改善患者的神经功能缺损程度及治疗效果，安全性较高，值得临床推广应用。

关键词：急性脑梗死；大剂量阿托伐他汀；尿激酶；神经功能缺损评分

中图分类号：R743.3文献标志码：A文章编号：2096-1413(2016)27-0063-02

The clinical efficacy of high dose atorvastatin combined with urokinase in the treatment of acute cerebral infarction
WANG Pei-jun
(Department of Neurology, People`s Hospital of Qianyang County, Baoji 721100, China)

ABSTRACT: Objective To investigate the clinical efficacy of high dose atorvastatin combined with urokinase on patients with acute cerebral infarction. Methods Seventy -eight cases of patients with acute cerebral infarction admitted in our hospital were selected, and were randomly divided into treatment group and control group. The treatment group was given 40 mg/d atorvastatin and urokinase, while the control group was given 10 mg/d atorvastatin and urokinase. The clinical efficacy, adverse reactions and ESS scores of two groups were observed before treatment and 1, 7, 14 d after treatment. Results There was no statistical difference in ESS score between two groups at 1 d before treatment; the ESS scores of two groups were significantly increased after treatment (P<0.05); compared with contral group, the ESS scores of observation group were significantly higher (P<0.05). The total effective rate of the treatment group was higher than that of the control group (P<0.05). There was no significant difference in adverse reactions of two groups (P<0.05). Conclusion The high dose atorvastatin combined with urokinase could effectively improve the nerve function defect degree and treatment efficacy, which is worthy of clinical promotion and application.
KEYWORDS: acute cerebral infarction; high dose atorvastatin; urokinase; nerve function defect score

参考文献：
[1] 关晖勇,黄眧海,陈愉快.阿托伐他汀联合甲钴胺对脑梗死患者C 反应蛋白、同型半胱氨酸和血脂的调控作用[J].实用医学杂志,2016,32(4):640-642.
[2] 李强,凌芳,聂德云,等.大剂量阿托伐他汀对急性脑梗死患者血清细胞因子及动脉粥样硬化斑块的影响[J].重庆医学,2012,41(16):1598-1600.
[3] 杨保华,叶晓林.不同剂量阿托伐他汀联合阿司匹林对急性脑梗死患者脑血流指标以及颈动脉粥样斑块的影响[J].医学综述,2016,22(6):1201-1204.
[4] 中华神经科学会,中华神经外科学会.各类脑血管疾病诊断要点 [J].中华神经科杂志,1996,29(2):379-380.
[5] 赵慧新,赵会媛,闫奕,等.急性脑梗死合并阻塞性睡眠呼吸暂停低 通气综合征患者颈动脉内-中膜厚度及血清基质金属蛋白酶9 水平 变化[J].中国全科医学,2014,17(24):2859-2861.
[6] 庄献博,徐光军,王未飞,等.阿托伐他汀对急性脑梗死患者外周血辅助性T细胞17及调节性T细胞平衡的影响[J].中华老年心脑血管病杂志,2015,17(10):1096-1098.
[7] 司友锋.阿托伐他汀对急性脑梗死患者神经功能、血清NO水平及脑血管储备的影响[J].山东医药,2015,55(32):44-45.
[8] 谢坚,张虹桥,章成国,等.瑞舒伐他汀与阿托伐他汀对急性脑梗死患者血脂、血清超敏C 反应蛋白及颈动脉粥样硬化斑块作用的比较 [J].临床神经病学杂志,2015,28(1):37-41.
[9] 杨华清.大剂量阿托伐他汀对急性脑梗死患者血清炎症因子水平及颈动脉内膜中层厚度的影响[J].山东医药,2014,54(23):72-74.
[10] 夏明栓.阿司匹林联合阿托伐他汀钙对急性脑梗死患者C 反应蛋白的影响[J].中西医结合心脑血管病杂志,2015,13(4):549-550.